Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Equity Ratio (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Equity Ratio for 4 consecutive years, with 0.72 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 61.26% to 0.72 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.72 through Dec 2025, up 61.26% year-over-year, with the annual reading at 0.72 for FY2025, 61.26% up from the prior year.
  • Equity Ratio hit 0.72 in Q4 2025 for Taysha Gene Therapies, up from 0.69 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.75 in Q2 2025 to a low of 0.46 in Q2 2023.
  • Historically, Equity Ratio has averaged 0.29 across 4 years, with a median of 0.37 in 2025.
  • Biggest YoY gain for Equity Ratio was 5672.72% in 2023; the steepest drop was 361.28% in 2023.
  • Year by year, Equity Ratio stood at 0.01 in 2022, then soared by 5672.72% to 0.43 in 2023, then increased by 2.81% to 0.45 in 2024, then surged by 61.26% to 0.72 in 2025.
  • Business Quant data shows Equity Ratio for TSHA at 0.72 in Q4 2025, 0.69 in Q3 2025, and 0.75 in Q2 2025.